| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Beyond Air, Inc.$0.42
-0.01 (-1.24%)
D 27Pipeline Score MedTech · Clinical
Market Cap
5.09 M
EPS
-5.42
P/E Ratio
-
Value Trade
37.18 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.91 M
R&D Expenses
2.28 M
Operating CF
-4.54 M
Total Assets
35.38 M
Total Liabilities
29.18 M
Equity
6.13 M
D/E Ratio
12,345
-13.93 %
Week
-22.88 %
1 Month
-63.55 %
3 Month
-67.4 %
6 Month
-99.61 %
5 Year
-99.94 %
All Time
Cash Data
Cash Position
11.64 M
Monthly Burn
1.51 M
Runway
7.4 mo
Burn Trend
SEC Filing
Jun 26, 2026
Overview
Volume
238.98 K
52 Week Range
0.38 - 5.84
% held by Insiders
2.27 %
% held by Institutions
9.66 %
Enterprise Value
11.01 M
Total Shares
10.52 M
Short %
3.34 %
Float Shares
9.92 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Beyond Air, Inc.
398Total events
8Upcoming
104Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 8
TBD
T2Milestone Payment
Up to $5.5 million clinical milestone payments to Beyond Air from Phase 1 through NDA submission
Event history 390
Jun 26, 2026
◆Quarterly UpdateCorporate
Fiscal Year End 2026 Financial Results Conference Call and Webcast
Jun 26, 2026
▲Partnership / LicenseCorporate
Awarded national group purchasing agreement with leading U.S. GPO
hypoxic respiratory failuresource ↗
Jun 18, 2026
▼Reverse Stock SplitCorporate
Board approved 1-for-20 reverse stock split to regain Nasdaq compliance
May 7, 2026
◆Oral PresentationPresentation
Beyond Air to participate in D. Boral Capital Global Conference 2026
Apr 19, 2026
◆Poster PresentationUNOPresentation
Poster presentation of Phase 1 data on intratumoral UNO at AACR Annual Meeting 2026
solid tumor metastasessource ↗
Apr 1, 2026
▲Product LaunchPost-Market
National group purchasing agreement awarded with a top 3 U.S. GPO for LungFit PH
hypoxic respiratory failure in term and near-term neonatessource ↗
Apr 2026
◆Oral PresentationUNOPresentation
Phase 1a data from UNO program to be presented at AACR 2026
solid tumorssource ↗
Mar 26, 2026
Drug Pipeline Intelligence
D27
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 28%
Micro Cap (rank 657 of 911)
Percentile RankBeyond Air, Inc. faces pipeline headwinds (27/100), with $97M risk-adjusted pipeline value, led by Nitric Oxide in Bronchiolitis Acute (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nitric Oxide Small molecule | Bronchiolitis | Phase 3 | NCT01768884 | 50% | $97M | COMPLETED | 112 | - | - | Jan 1, 2016 | - | May 4, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LungFit GO | NTM Lung Infection | — | 2022-10-17 | total subjects: 15; mean age: 62.1; female percentage: 75; titration dose: 250 ppm; inhalations administered: 2492; treatment compliance: >90%; serious adverse events: 0; culture conversion: 1 Read More | Beyond Air Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit GO at the CHEST Annual Meeting 2022 - Data show favorable safety, tolerabilit Read More | |
LungFit GO | NTM Lung Infection | — | 2022-10-17 | total subjects: 15; mean age: 62.1; female percentage: 75; titration dose: 250 ppm; inhalations administered: 2492; treatment compliance: >90%; serious adverse events: 0; culture conversion: 1 Read More | Beyond Air Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit GO at the CHEST Annual Meeting 2022 - Data show favorable safety, tolerabilit Read More | |
LungFit GO | NTM Lung Infection | — | 2022-10-17 | total subjects: 15; mean age: 62.1; female percentage: 75; titration dose: 250 ppm; inhalations administered: 2492; treatment compliance: >90%; serious adverse events: 0; culture conversion: 1 Read More | Beyond Air Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit GO at the CHEST Annual Meeting 2022 - Data show favorable safety, tolerabilit Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XAIR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XAIR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XAIRBeyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Beyond Air, Inc. reported a 107% increase in revenue for fiscal year 2026, reaching $7.7 million. The company announced positive revenue guidance for 2026 and 2027, anticipating significant growth driven by the second-generation LungFit PH system, currently under FDA review. Despite a net loss of $33.2 million, the company is optimistic about its future market opportunities.
Read more →XAIR▲ +14.4%on this newsshared move
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
Beyond Air, Inc. has announced a conference call to discuss its fiscal year-end financial results for 2026. The call is scheduled for June 26, 2026, at 8:00 am ET. The company specializes in medical devices and biopharmaceuticals, particularly utilizing nitric oxide for treating respiratory and neurological conditions. They have received FDA approval for their LungFit PH system.
Read more →XAIRBeyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Beyond Air, Inc. is urging stockholders to vote 'FOR' all proposals at the upcoming Special Meeting scheduled for June 18, 2026. The Board of Directors recommends this action to address a potential delisting from Nasdaq due to the company's stock price falling below the required minimum. A reverse stock split is proposed to increase the stock price above $1.00, which is critical for maintaining access to capital markets and investor eligibility.
Read more →XAIR▲ +5.7%on this news
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
Beyond Air, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon regaining compliance with the Bid Price Rule by July 31, 2026. The company is currently compliant with other listing requirements. A special meeting for shareholders to vote on a proposed reverse stock split is scheduled for June 18, 2026. CEO Robert Goodman expressed confidence in the company's compliance plan and ongoing commercial initiatives.
Read more →XAIR▼ -11.6%on this news· ran to -22% by day 1
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
Beyond Air, Inc. announced its participation in the D. Boral Capital Global Conference 2026, scheduled for May 7th at The Plaza Hotel in New York. CEO Robert Goodman and CFO Dan Moorhead will represent the company. Beyond Air focuses on using nitric oxide to treat respiratory illnesses and has received FDA approval for its LungFit PH system.
Read more →XAIRBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
Beyond Air, Inc. has secured a national group purchasing agreement for its LungFit PH system, effective April 1, 2026. This agreement enhances access for nearly 2,000 hospitals and health systems in the U.S. The partnership with leading GPOs aims to streamline the adoption of the tankless nitric oxide solution, supporting efficient healthcare delivery.
Read more →XAIR▼ -6.7%on this news
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
Beyond Air, Inc. announced the resignation of CEO Steve Lisi and the appointment of Robert Goodman as the new CEO. Lisi, who led the company for nine years, is stepping down to pursue other opportunities. Goodman, previously the Chief Commercial Officer, is expected to enhance the company's commercial execution and expand market adoption of their LungFit PH technology.
Read more →XAIR▼ -7.3%on this news
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
Beyond Air, Inc. commented on a new independent review highlighting the antimicrobial effects of high-dose inhaled nitric oxide (iNO). The article presents evidence that high-dose iNO may serve as a broad-spectrum therapy for respiratory infections. It reviews data from 27 studies and suggests future research opportunities in various pulmonary conditions.
Read more →XAIRBeyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Beyond Air, Inc. reported a 105% increase in revenue for fiscal Q3 2026, reaching $2.2 million. The company maintains its revenue guidance of $8-10 million for the fiscal year. A binding letter of intent was signed for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS, potentially providing up to $32.5 million. Additionally, Phase 1a data from the UNO program will be presented at the AACR Annual Meeting in April 2026.
Read more →XAIRBeyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
Beyond Cancer, Ltd. has been selected to present Phase 1 trial data on intratumoral ultra-high concentration nitric oxide (UNO) at the AACR Annual Meeting 2026. This presentation highlights the potential of UNO as an immunotherapeutic for solid tumors. The event will take place from April 17-22, 2026, in San Diego, California.
Read more →XAIR▼ -14.2%on this news
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Beyond Air, Inc. has announced a private placement of $5 million, issuing nearly 3.93 million shares of common stock and associated warrants. The placement is priced at $1.272 per share, with expected gross proceeds to be used for working capital and corporate purposes. The closing is anticipated around January 16, 2026, pending customary conditions.
Read more →XAIR▼ -14.2%on this newsshared move
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has announced the acquisition of 85% of NeuroNOS, a company focused on developing disease-modifying therapies for Autism Spectrum Disorder. This acquisition is significant as it addresses a critical unmet need, with no FDA-approved therapies currently available. NeuroNOS is led by a team that includes two Nobel Laureates, enhancing its scientific foundation. The acquisition also comes with FDA Orphan Drug designations for related conditions, promising a strong market position.
Read more →XAIR▲ +150%on this newsshared move
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has announced the acquisition of 85% of NeuroNOS, a subsidiary of Beyond Air, which focuses on developing disease-modifying therapies for Autism Spectrum Disorder. This acquisition is significant as it aims to address the urgent need for effective treatments in a market where no FDA-approved options currently exist. The collaboration includes notable scientific leadership, including two Nobel Laureates, and has secured FDA Orphan Drug designations for related conditions.
Read more →XAIRBeyond Air® Appoints Dan Moorhead as Chief Financial Officer
Beyond Air, Inc. has appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Moorhead, who has over 20 years of finance leadership experience, will support the company's commercial strategy as it prepares for the FDA approval of its second generation LungFit PH. Duke Dewrell will return to his role as Controller after serving as interim CFO.
Read more →XAIRBeyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil
Beyond Air, Inc. has signed international distribution agreements for its LungFit PH device, expanding its reach to 39 countries, including Germany and Brazil. This expansion is expected to enhance market share and improve hospital operations with its innovative nitric oxide delivery system. The company anticipates significant benefits for patients starting in 2026.
Read more →XAIRBeyond Air® Announces Transition of Chief Financial Officer
Beyond Air, Inc. announced the resignation of CFO Doug Larson, who will remain until December 5, 2025, to ensure a smooth transition. Duke Drewell, the current Controller, will take over as interim CFO. Larson's contributions were pivotal during the company's transition to a commercial stage, and he will continue to support the company in an advisory role.
Read more →XAIRBeyond Air Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief
Beyond Air, Inc. reported substantial financial growth in the fiscal second quarter of 2026, achieving a 128% increase in revenue, amounting to $1.8 million. The company appointed Bob Goodman as Interim Chief Commercial Officer and made significant strides in expanding its international distribution network for its LungFit PH device. While the gross loss decreased compared to the previous year, the company still faces challenges with a reported long-term debt. Additionally, Beyond Air is gearing up for regulatory submissions and aims to launch the second-generation LungFit PH by the end of 2026.
Read more →XAIR▼ -16.1%on this newsshared move
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Beyond Air, Inc. reported a significant revenue increase of 128% year-over-year, reaching $1.8 million for the fiscal second quarter ended September 30, 2025. The company appointed Bob Goodman as Interim Chief Commercial Officer and raised $12 million in debt financing. They updated their revenue guidance for fiscal year 2026 to between $8 and $10 million, while also reporting a net loss of $7.9 million for the quarter.
Read more →XAIRBeyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air has secured up to $32 million in financing through a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital. This funding aims to accelerate the commercial expansion of its LungFit PH device. The company anticipates achieving profitability based on projected global revenues and plans to launch a second-generation device by the end of 2026.
Read more →XAIRBeyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Beyond Air, Inc. will report its financial results for the second fiscal quarter on November 10, 2025. The company is focused on developing nitric oxide-based therapies for various medical conditions and has received FDA approval for its LungFit®PH system. A conference call and webcast will follow the financial results announcement.
Read more →XAIR▲ +5.4%on this news
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
Beyond Air, Inc. will participate in the ROTH 4th Annual Healthcare Opportunities Conference on October 9, 2025. CFO Douglas Larson will be available for investor meetings at the event. The company focuses on nitric oxide therapies for respiratory and neurological conditions and has received FDA approval for its LungFit®PH system.
Read more →XAIR▼ -5.2%on this news· ran to -35% by day 3
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
Beyond Air, Inc. has announced the exercise of certain outstanding common warrants, resulting in gross proceeds of approximately $3.25 million. The funds will be utilized to advance clinical and pre-clinical programs, as well as for operational expenses. The offering is expected to close on September 9, 2025, subject to customary conditions.
Read more →XAIR▲ +49.8%on this newsshared move
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
NeuroNOS has been granted Orphan Drug Designation by the FDA for its investigational therapy BA-101, targeting glioblastoma, a highly aggressive brain cancer. This designation underscores the significant unmet medical need for effective treatments in this area. The company believes that its approach to modulating nitric oxide levels could lead to improved patient outcomes.
Read more →XAIRBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Beyond Air, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Steve Lisi will present, and an on-demand webcast will be available. The company focuses on nitric oxide therapies for respiratory and neurological conditions and has FDA-approved products.
Read more →XAIR▼ -6.6%on this news
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
Beyond Air, Inc. has announced new international distribution agreements for its LungFit PH technology in Japan, South Korea, and several Central American countries, expanding its reach to 34 countries. This expansion aims to enhance patient care by utilizing a tankless nitric oxide delivery system, which is already approved for commercial use in the U.S. and EU. The company anticipates significant adoption and impact in both developed and emerging markets.
Read more →XAIRBeyond Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
Beyond Air, Inc. reported a 157% year-over-year increase in revenue for the fiscal first quarter of 2026, generating $1.8 million. The company also reaffirmed its revenue guidance for the full fiscal year at $12 to $16 million, supported by strong demand for its LungFit PH system. Despite these positive indicators, Beyond Air reported a loss of $7.7 million and substantial cash burn of $4.7 million, highlighting ongoing financial pressures.
Read more →XAIR▼ -29%on this news
Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended
Beyond Air, Inc. reported a significant revenue increase of 220% for the fiscal year ending March 31, 2025, totaling $3.7 million. The company anticipates revenue between $12 million and $16 million for FY 2026, attributed to its expanding distribution of the LungFit PH device. With over 45 hospitals currently using this device and positive regulatory advancements, Beyond Air expresses optimism for future growth. Despite these positives, the company still faces challenges, including high operational costs and substantial net losses for the year.
Read more →XAIR▲ +5.6%on this news
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highes
NeuroNOS has announced the successful acquisition of $2 million in funding to further develop an innovative therapy aimed at treating Autism Spectrum Disorder (ASD). This small-molecule drug is designed to regulate nitric oxide levels in the brain, with preclinical studies showing promising results. The company plans to initiate first-in-human studies in 2026 and is currently optimizing the drug's delivery method. NeuroNOS aims to address a significant treatment gap for children with ASD, preparing for possible oral and injectable formulations.
Read more →XAIRBeyond Air Announces Agreements Expanding Global Distribution of LungFit PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 co
Beyond Air has announced new distribution agreements for its LungFit PH system in France, Turkey, Romania, and Morocco, expanding its international market presence to 18 countries. The company anticipates a quicker commercial ramp-up in international markets compared to the U.S., aided by established distribution partners. This product allows for on-demand nitric oxide generation, enhancing hospital efficiency and reducing safety risks associated with traditional high-pressure cylinders. The LungFit PH system has recently received CE Mark approval and is already being utilized by leading hospitals in the U.S.
Read more →XAIRBeyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended
Beyond Air, Inc. (NASDAQ: XAIR) reported a 34% revenue increase for Q3 fiscal 2025, exceeding $1 million. The company received a CE Mark for its LungFit PH, which will enable market expansion in Europe and Australia. Beyond Air anticipates regulatory approvals in eight countries by year-end, and has made significant progress in commercial efforts within the U.S. Despite the positive revenue growth, the company faces challenges such as operational costs exceeding revenue and substantial outstanding debt.
Read more →XAIRBeyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement Garden City, NY
Beyond Air, Inc. has been granted a 180-day extension by Nasdaq to regain compliance with its minimum bid price requirement. The extension allows the company until August 4, 2025, to meet the standard of a minimum closing bid price of $1.00 per share. The company has reported that it is currently meeting all other requirements set by Nasdaq. However, Beyond Air did not regain compliance during the previous compliance period, raising concerns about its financial stability.
Read more →XAIR▲ +7.8%on this news
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy - The Phas
Beyond Cancer has received approval from the Israeli Ministry of Health to initiate a Phase 1b clinical trial evaluating the use of Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) alongside anti-PD-1 therapy. This trial will focus on patients with unresectable solid tumors who have not sufficiently responded to previous treatments. The study aims to assess the treatment's efficacy and safety, with topline results expected in late 2025. This research is part of Beyond Cancer's broader strategy to develop innovative cancer therapies.
Read more →XAIRBeyond Air Receives CE Mark in Europe for the LungFit PH System Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function
Beyond Air has received CE mark approval for its LungFit PH system, allowing the company to market the device in Europe and other regions. This approval specifically covers treatment for newborn infants experiencing hypoxic respiratory failure and for managing peri- and post-operative pulmonary hypertension. The company expects to initiate shipments to its Asia-Pacific partner, Getz Healthcare, which will trigger a $1 million milestone payment. The LungFit PH system enhances sustainability in healthcare by generating nitric oxide from ambient air, eliminating the need for traditional storage tanks and reducing environmental impact.
Read more →XAIRBeyond Air Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended
Beyond Air, Inc. reported a 17% increase in revenues for its fiscal second quarter 2025 compared to the previous quarter, alongside a 60% increase in hospital contracts. The company has strengthened its cash runway through strategic financing, including a $20.6 million private placement. However, it faced a loss of $1.2 million during this quarter and a significant cash burn. Looking forward, the company continues to enhance its commercial strategy with new partnerships and is awaiting regulatory decisions that could impact its LungFit PH system's market penetration.
Read more →XAIRBeyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 - - Retiring
Beyond Air, Inc. has announced a $20.6 million private placement offering, expected to enhance its balance sheet by providing sufficient cash runway through June 2026. The financing includes the retirement of $17.5 million in debt, eliminating significant future debt payments. Insiders and institutional investors have contributed to the offering, demonstrating confidence in the company's future, particularly its LungFit PH system. The private placement is set to close on September 30, 2024, pending certain conditions.
Read more →XAIRBeyond Air Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 45% compared to the previous quarter ended
Beyond Air, Inc. reported a 45% increase in revenue for the fiscal first quarter of 2025, compared to the previous quarter, driven by the success of its LungFit PH device. The company communicated positive momentum in customer engagement and has set a revenue guidance of at least $10 million for FY 2025. Despite the strong revenue growth, Beyond Air faced a net loss of $12.2 million and witnessed rising operational costs and headcount reductions. Future prospects include key regulatory submissions and potential market expansions for its product offerings.
Read more →XAIR▲ +8.1%on this news· ran to -53% by day 3
Beyond Air Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device e
Beyond Air reported its fiscal fourth quarter and full year 2024 financial results, highlighting significant changes in corporate leadership and updates on its LungFit PH device. The company has appointed David Webster as the new Chief Commercial Officer to enhance commercial operations and revised its revenue guidance to over $10 million for FY 2025 due to expectations of accelerating growth. However, it has also faced challenges, including cash burn and delays in certain product developments, prompting a strategic focus on capital conservation.
Read more →XAIRBeyond Air Appoints David Webster as Chief Commercial Officer Mr. Webster brings more than 20 years of executive level experience in the life sciences industry
Beyond Air, Inc. has appointed David Webster as Chief Commercial Officer, effective July 8, 2024, bringing over 20 years of executive experience in the life sciences sector. This strategic move comes as the company prepares for significant market opportunities with its LungFit PH system in the nitric oxide market. Webster's background includes successful commercial strategies in the hospital space, along with previous leadership roles in medical device companies. The company has received positive customer feedback following updates to its LungFit system during its initial soft launch.
Read more →XAIRBeyond Air Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
Beyond Air, Inc. has announced the pricing of a $16.0 million registered direct offering of common stock and warrants. The offering includes 9,638,556 shares at a price of $1.66 per share, with warrants exercisable at $2.25. The capital raised is intended to support commercial sales, research, and general corporate purposes. The closing of the offering is expected on or around March 22, 2024, pending customary closing conditions.
Read more →XAIR▲ +15%on this news
Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2024 Commercial demand for LungFit PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expans
Beyond Air, Inc. reported strong financial results for Q3 2024, showcasing over 60% sequential revenue growth driven by rising demand for its LungFit PH device. The company received FDA acceptance for a PMA supplement to expand LungFit PH's label for cardiac surgeries and is progressing with a pilot trial for LungFit PRO in treating viral community-acquired pneumonia. Despite the positive commercial traction, Beyond Air faced a net loss of $16.2 million during the quarter due to heightened operating and development costs. The fiscal year 2025 revenue guidance has been reaffirmed at $12 - $16 million.
Read more →XAIRBeyond Air Reports Financial Results for Second Quarter of Fiscal Year 2024 Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit PRO to treat viral community acquired pneumonia (VCAP)
Beyond Air has reported its financial results for Q2 of Fiscal Year 2024, revealing a revenue guidance of $12 - $16 million for FY 2025. The company is advancing its pilot trial of LungFit PRO for treating viral community acquired pneumonia, with anticipated data by mid-2024. Positive data regarding its UNO therapy was shared at the Society for Immunotherapy Conference, indicating safety and immune activation. Despite these advancements, the company experienced an increase in net loss attributed to common stockholders and operational expenses.
Read more →XAIRBeyond Air and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment t
Beyond Air, Inc. has entered a strategic collaboration with Getz Healthcare to commercialize its LungFit PH device in the Asia-Pacific region. The partnership will allow Beyond Air to access hospitals across multiple countries, including Australia and Singapore, once regulatory approvals are received. Getz Healthcare will assist with logistics and provide customer support while Beyond Air will supply the device and accessories. This collaboration aims to enhance the availability of nitric oxide therapy in key growth markets.
Read more →XAIRBeyond Air Reports Financial Results for First Quarter of Fiscal Year 2024 Reported commercial sales for LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in exce
Beyond Air reported financial results for the first quarter of fiscal year 2024, showing over $1 million in annual commercial sales for its LungFit PH system, which is designed for treating neonates with hypoxic respiratory failure. The company has also secured FDA approval to conduct a clinical study in U.S. patients hospitalized with viral community-acquired pneumonia this winter. In addition, Beyond Air is focusing on research and development, including a program targeting autism spectrum disorder. Despite these advancements, the company faced a net loss of $14.1 million in the quarter, driven by increased development costs.
Read more →XAIRBeyond Air Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for Lung
Beyond Air, Inc. reported its financial results for the fourth quarter and fiscal year ending March 31, 2023. The company successfully completed phase 1 of its U.S. commercial launch for LungFit PH, signing multiple hospitals, and has initiated phase 2 of the launch. They showcased positive preclinical data for ultra-high concentration nitric oxide therapy, aimed at treating solid tumors, during the AACR 2023 meeting. Despite these advancements, the company incurred a GAAP net loss of $59.4 million for the fiscal year, an increase from the previous year, alongside rising operational costs.
Read more →XAIRBeyond Air Secures up to $40 Million Debt Financing Funding to support the commercialization of LungFit PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air's revolutionar
Beyond Air, Inc. has secured up to $40 million in senior secured debt financing from Avenue Capital Group. This funding aims to bolster the commercialization of its LungFit PH device and further the clinical development of its revolutionary nitric oxide treatment platform. The financing consists of three tranches, with the initial $17.5 million available at closing. This strategic move enhances Beyond Air's financial stability and showcases the potential of their technology for treating respiratory conditions.
Read more →XAIR▼ -5.8%on this news
Beyond Air Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval Garden City, NY
Beyond Air, Inc. has appointed Dr. Jeff Myers, M.D., Ph.D., as its new Chief Medical Officer, effective March 27, 2023. With extensive experience in clinical development and regulatory affairs, Dr. Myers has previously held senior roles in several biopharmaceutical companies. His appointment is aimed at enhancing the company's efforts in developing its LungFit platform for respiratory conditions and solid tumors. Dr. Andrew Colin, the outgoing CMO, will transition to Senior Medical Director Global Clinical Leadership, ensuring continuity in leadership.
Read more →XAIR▼ -6.2%on this news
Beyond Air Reports Financial Results for the Third Quarter of Fiscal Year 2023 U.S. commercial launch continues for LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented p
Beyond Air, Inc. has reported its financial results for the third quarter of fiscal year 2023, highlighting the continuous launch of its LungFit PH system for treating neonates with respiratory failure. The company has made promising strides in nitric oxide therapies and presented encouraging combination therapy data at recent oncology meetings. Despite reporting a significant net loss and rising expenses, the company anticipates regulatory advances and the potential for meaningful sales in the upcoming quarter.
Read more →XAIRBeyond Air Reports Financial Results for the Second Quarter of Fiscal Year 2023 Commercial launch underway for LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received
Air Reports Financial Results the Second Quarter of Fiscal Year 2023 launch underway for LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 favorable safety, tolerability, and efficacy res
Read more →XAIRBeyond Air Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit GO at the CHEST Annual Meeting 2022 - Data show favorable safety, tolerabilit
Positive Data from At-Home Pilot Study in Patients with NTM Lung Infection Treated with (NO) using the LungFit GO at the CHEST Annual Meeting 2022 Data show favorable safety, tolerability, and efficacy results - All patients titrated to 250 ppm NO with no patients needing to r
Read more →XAIR▲ +10.1%on this news
Beyond Air Affiliate Beyond Cancer Doses Initial Patient in First-in-Human Phase 1 Study of Ultra- High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) GARDEN CITY, N.Y. and
Air Affiliate Beyond Cancer Doses Initial Patient in First-in-Human Phase 1 Study of Ultra- Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 - Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR
Read more →XAIRBeyond Air Reports Financial Results for the First Quarter of Fiscal Year 2023 Initiated U.S. commercial launch of LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which recei
Air Reports Financial Results the First Quarter of Fiscal Year 2023 U.S. commercial launch of LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 present data from the pilot study of at-hom
Read more →XAIR▼ -7.8%on this news· ran to +18% by day 3
Beyond Air Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 LungFit PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on
Air Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun positive data for high-
Read more →XAIRBeyond Air Reports Financial Results for the Third Quarter of Fiscal Year 2022 LungFit PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half
Air Reports Financial Results for the Third Quarter of Fiscal Year 2022 PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark $30 million for oncolo
Read more →XAIRBeyond Air Provides Regulatory Update for LungFit
Air Provides Regulatory Update for LungFit PH CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respirato
Read more →XAIRBeyond Air Reports Financial Results for the Second Quarter of Fiscal Year 2022 U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit PH to treat persistent pulmonary hypertension of the newborn (PP
Air Reports Financial Results for the Second Quarter of Fiscal Year 2022 FDA actively reviewing premarket approval (PMA) submission for LungFit PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth quarter of ca
Read more →XAIRBeyond Air Announces Formation of Beyond Cancer , a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors $23.9 million committed in concurrent equity private pla
Air Announces Formation of Beyond Cancer , a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors million committed in concurrent equity private placement to form Beyond Cancer that will leverage Beyond Air's nitric oxi
Read more →XAIRBeyond Air Reports Positive Interim Results for LungFit GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease Interim results show that 250
Air Reports Positive Interim Results for LungFit GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, for Nontuberculous Mycobacterial Lung Disease results show that 250 parts per million (ppm) nitric oxide (NO) was well-tolerated with no study disco
Read more →XAIRBeyond Air Provides Global Regulatory Update for LungFit PH FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval Stage 1 Assessment Audit in the CE Mark proce
Air Provides Global Regulatory Update for LungFit PH inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval 1 Assessment Audit in the CE Mark process is complete; expect to receive CE Mark in 1H CY2022 CITY, N.Y., Sept. 2
Read more →XAIR▼ -5.2%on this news
Beyond Air Announces CFO Transition
Air Announces CFO Transition CITY, N.Y., August 20, 2021 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions,
Read more →XAIRBeyond Air Reports Financial Results for the First Quarter of Fiscal Year 2022 U.S. FDA reviewing premarket approval (PMA) submission for LungFit PH to treat persistent pulmonary hypertension of the newborn (PPHN); On tr
Air Reports Financial Results for the First Quarter of Fiscal Year 2022 FDA reviewing premarket approval (PMA) submission for LungFit PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of calendar year 2021
Read more →XAIRBeyond Air Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021 Submitted first premarket approval (PMA) application in the Company's history to FDA for LungFit PH to treat persistent pulmonary hypertens
Air Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021 first premarket approval (PMA) application in the Company's history to FDA for LungFit PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial launch in the
Read more →XAIRBeyond Air Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit PRO Programs at ATS 2021 Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (inc
Air Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit PRO Programs at ATS analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with
Read more →XAIRBeyond Air Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease Award will help fun
Air Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease will help fund the development of high concentration nitric oxide (NO) for Nontuberc
Read more →XAIRBeyond Air Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update U.S. FDA reviewing premarket approval (PMA) submission for LungFit TM PH to treat persistent pulmonary hypertension
Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization r
Read more →XAIRBeyond Air Initiates Patient Screening for LungFit GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease Expect to dose first patient in January 2021 and repo
Air Initiates Patient Screening for LungFit GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease to dose first patient in January 2021 and report interim data mid-2021 in nontuberculous mycobacteria (NTM) at-home s
Read more →XAIRBeyond Air Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinde
Air Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating improved economics and safety in hospital be subject to a 180-day revie
Read more →XAIRBeyond Air Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update U.S. COVID-19 study showing positive safety profile for patients enrolled to date PMA for LungFit TM PH to treat per
Air Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update COVID-19 study showing positive safety profile for patients enrolled to date for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN) expected to be submitt
Read more →XAIRBeyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020 Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary en
Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020 positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary first patient in the U.S. COVID-19 study using the LungFit system positive
Read more →XAIRBeyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors Globenewswire
Air Announces Positive Preclinical Data Supporting High Nitric Oxide as a Potential Treatment for Solid Tumors Globenewswire June 22, 2020 demonstrate the ablation of solid tumors with nitric oxide tumor-bearing mice treated with nitric oxide rejected a second tumor challenge
Read more →XAIRBeyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit in COVID-19 Patients Anticipate study start in June 2020 Garden City, NY
Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit in COVID-19 study start in June 2020 City, NY, May 26, 2020 - Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on develop
Read more →XAIRBeyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both t
Air Achieves Primary Endpoint in Pilot Bronchiolitis Study concentration nitric oxide (150 ppm) is statistically significant to both low concentration nitric oxide (85 ppm) and control on both the primary endpoint and the key secondary endpoint serious adverse events related
Read more →XAIRBeyond Air Enters into New Common Stock Purchase Agreement Extending Relationship with Lincoln Park Capital Term to run through May 2023 Available capital under the new purchase agreement is $40 Million Garden City, NY
Air Enters into New Common Stock Purchase Agreement Extending Relationship with Lincoln Park Capital to run through May 2023 capital under the new purchase agreement is $40 Million City, NY, May 15, 2020 - Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and b
Read more →XAIRBeyond Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United States Food and Drug Administration (FDA) agrees to a trial using the LungFit system t
Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United and Drug Administration (FDA) agrees to a trial using the LungFit system to treat COVID-19 patients pending with Health Canada and the Israel Ministry
Read more →XAIRBeyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients LungFit BRO system to be used in proposed study to treat COVID-19 p
Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of BRO system to be used in proposed study to treat COVID-19 patients applications have been submitted to the Biomedical Advance Research and Development
Read more →XAIRBeyond Air Hosting Analyst Day Today
Air Hosting Analyst Day Today, March 5, 2020 at 2:00 p.m. ET new program targeting solid tumors with nitric oxide a $25 million line of credit remain on track for PPHN, BRO and NTM programs City, NY, and Rehovot, Israel, March 5, 2020 - Beyond Air, Inc. (NASDAQ: XAIR), a clin
Read more →XAIRBeyond Air Signs Agreement with MESA Specialty Gases & Equipment for Nitric Oxide and Nitrogen Dioxide Calibration Gas Supply GlobeNewswire
Air Signs Agreement with MESA Specialty Gases & Equipment for Nitric Oxide and Nitrogen Dioxide Calibration Gas Supply five-year global agreement for all LungFit systems CITY, N.Y. and REHOVOT, Israel, Nov. 25, 2019 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR), a clinica
Read more →XAIRBeyond Air Reports Financial Results for Fiscal First Quarter 2020 Began trading under new ticker symbol, XAIR, on the NASDAQ stock exchange on
Air Reports Financial Results for Fiscal First Quarter 2020 trading under new ticker symbol, XAIR, on the NASDAQ stock exchange on July 15, 2019 submitting a PMA for LungFit * for the treatment of persistent pulmonary hypertension of the newborn (PPHN) in the third quarter of
Read more →XAIRBeyond Air TM Announces New NASDAQ Ticker Symbol is XAIR New Ticker, XAIR , to be effective Monday
AirTM Announces New NASDAQ Ticker Symbol is XAIR Ticker, XAIR, to be effective Monday, July 15, 2019 City, NY, and Rehovot, Israel, July 15, 2019 - Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitr
Read more →XAIRCORRECTING and REPLACING - AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results GlobeNewswire
and REPLACING - AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results uplisting to the NASDAQ and $7.96 million PIPE financing PMA submission in the third quarter of calendar 2019 CE Mark in the first half of calendar 2020 licensing ag
Read more →XAIRAIT Therapeutics Announces $8 Million PIPE Financing Garden City, NY, and Rehovot, Israel
Therapeutics Announces $8 Million PIPE Financing City, NY, and Rehovot, Israel, June 4, 2019 - AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients wit
Read more →XAIRAIT Therapeutics Announces Uplisting to the Nasdaq Capital Market Trading expected to begin on
Therapeutics Announces Uplisting to the Nasdaq Capital Market expected to begin on May 7, 2019 City, NY, and Rehovot, Israel, May 3, 2019 - AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric
Read more →XAIRAIT Therapeutics, Inc. Condensed Proforma Consolidated Balance Sheet
Proforma Consolidated Balance Sheet Balance Sheet As Reported Proforma Adjustments Proforma Balance Sheet Assets Current assets Cash and cash equivalents $ 479,700 $ (479,700) (3)(4) $ - Restricted cash 15,912 - 15,912 Marketable secu
Read more →XAIRAIT Therapeutics Reports Financial Results for Fiscal Third Quarter 2019 Announced transformational partnership agreement with Circassia Pharmaceuticals PMA filing for treatment of PPHN on track for second quarter calend
Therapeutics Reports Financial Results for Fiscal Third Quarter 2019 transformational partnership agreement with Circassia Pharmaceuticals filing for treatment of PPHN on track for second quarter calendar 2019 treatment safely of a compassionate use NTM patient at 250 ppm nitr
Read more →XAIRAIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country AIT to
Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country to receive up to $32.5 million in up-front and regulatory milestones
Read more →XAIRAIT Therapeutics Appoints Douglas J. Beck as Chief Financial Officer Seasoned expert with three decades of financial planning and management experience to join AIT Team Garden City, NY, and Rehovot, Israel
Therapeutics Appoints Douglas J. Beck as Chief Financial Officer expert with three decades of financial planning and management experience to join AIT Team City, NY, and Rehovot, Israel, October 26, 2018 - AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device a
Read more →XAIRAIT Therapeutics Reports Financial Results for First Fiscal Quarter 2019 Started commercial development of ventilator compatible NO generator and delivery system - FDA 510(k) submission expected in the first quarter of c
Therapeutics Reports Financial Results for First Fiscal Quarter 2019 commercial development of ventilator compatible NO generator and delivery system - FDA 510(k) submission expected in the first quarter of calendar 2019 and in-vitro Nitric Oxide (NO) data presented at the 3rd
Read more →XAIRAIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund Garden City, N.Y., and Rehovot, Israel
Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund City, N.Y., and Rehovot, Israel, August 13, 2018 - AIT Therapeutics, Inc. (OTC:AITB) ("AIT Therapeutics or the "Company"), a clinical-stage medical device a
Read more →XAIRAIT Therapeutics Reports Financial Results for Three Months Ended
Therapeutics Reports Financial Results for Three Months Ended March 31, 2018 positive top-line data for Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study data from its inhaled Nitric Oxide study in patients infected with mycobacterium abscessus complex (MABSC) at the 2018 Amer
Read more →Competitive Position
How XAIR ranks across every disease it competes inCompetitive Position is a premium feature
See how XAIR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial